Comments
Cadila Healthcare on Thursday announced that the Drug Controller General of India has approved its New Drug Application for Saioglitazar for the treatment of Non-Cirrhotic Non-Alcoholic Steato Hepatitis (NASH) in India.
NASH is a progressive disease of the liver, which starts with fat accumulation in the liver known as Non-Alcohoiic Fatty Liver Disease (NAFLD). This condition could progress to cirrhosis and liver failure. Shareholders will closely monitor further progress.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.